scholarly journals 49 Aberrant Expression of CD5 in the Setting of B-Cell Acute Lymphoblastic Leukemia: A Case Report and Brief Review of the Literature

2018 ◽  
Vol 149 (suppl_1) ◽  
pp. S21-S22
Author(s):  
Elizabeth Staley ◽  
Eleanor McIntosh ◽  
Benjamin Hill
2003 ◽  
Vol 127 (5) ◽  
pp. 610-613
Author(s):  
Cherie H. Dunphy ◽  
Hendrik W. van Deventer ◽  
Kathryn J. Carder ◽  
Kathleen W. Rao ◽  
Georgette A. Dent

Abstract The translocation t(14;18)(q32;q21) is most commonly associated with follicular lymphoma but has also been described in acute lymphoblastic leukemia (ALL) of B-cell origin. Although these ALL cases have had a pre-pre-B, pre-B, or mature B-cell immunophenotype and L2 or L3 morphology, all have been associated with an abnormality of 8q24. In fact, 91% (10 of 11) have been associated with t(8;22) or t(8;14), marker chromosomes for Burkitt-type ALL. The other case was associated with del(8)(q24). Thus, Burkitt-type ALL may have various immunophenotypes and morphology when associated with t(14;18). We describe a case of mature B-cell ALL associated with t(14;18) and t(8;9)(q24;p13). The morphology was suggestive but not entirely characteristic of the L3 subtype. However, on the basis of the cytogenetic findings and the review of the literature, perhaps this case represents a variant of Burkitt-type ALL, which would be important to recognize for prognostic and therapeutic purposes. We describe our findings and review the literature to heighten awareness of this group of ALLs associated with t(14;18). Additional cases need to be accrued and documented to determine the significance of an associated abnormality of 8q24 in this setting.


2016 ◽  
Vol 57 (10) ◽  
pp. 2289-2297 ◽  
Author(s):  
Elisa Olga Sajaroff ◽  
Adrian Mansini ◽  
Patricia Rubio ◽  
Cristina Noemí Alonso ◽  
Marta S. Gallego ◽  
...  

2011 ◽  
Vol 5 (1) ◽  
Author(s):  
Muhammad N Siddique ◽  
Muhammad Popalzai ◽  
Nelly Aoun ◽  
Rabih Maroun ◽  
Michael Awasum ◽  
...  

2021 ◽  
pp. 1031-1039
Author(s):  
Ahmed Arafat ◽  
Dinara Sadykova ◽  
Ayrat Ziatdinov ◽  
Svetlana Senek ◽  
Natalya Samoilova ◽  
...  

SARS-CoV-2 which causes COVID-19 has been a great challenge to treat and deal with; despite strict measures that had been implemented by governments and organizations, worrying rates of morbidity and mortality are still being reported. Although available data have expressed that moderate or even mild forms of the disease are expected amongst most pediatrics cases, minimal data are available on the prognosis and the disease’s complications on the immunocompromised, especially oncology patients. We report a case of relapsed precursor B-cell acute lymphoblastic leukemia of a child with Down syndrome and COVID-19 and outline the treatment regimen that we used.


2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Ayed A. Algarni ◽  
Mojtaba Akhtari ◽  
Kai Fu

Myelodysplastic syndromes (MDS) comprise a group of heterogeneous clonal hematopoietic cell disorders characterized by cytopenias, bone marrow hypercellularity, and increased risk of transformation to acute leukemias. MDS usually transformed to acute myeloid leukemia, and transformation to acute lymphoblastic leukemia (ALL) is rare. Herein, we report a unique patient who presented with MDS with myelofibrosis. Two months after the initial diagnosis, she progressed to a precursor B-cell acute lymphoblastic leukemia. She was treated with induction therapy followed by allogenic stem cell transplantation. She was alive and doing well upon last followup. We have also reviewed the literature and discussed the clinicopathologic features of 36 MDS patients who progressed to ALL reported in the literature.


Sign in / Sign up

Export Citation Format

Share Document